Zentalis Q1 2025 cash $332.5M; first patient dosed in DENALI Part 2 azenosertib trial

Zentalis Pharmaceuticals, Inc.

2025-Q1 EPS reported -$0.67

Cash $332.5M (incl. $12.2M Immunome stock) at March 31, 2025; runway into late 2027.
First patient dosed in DENALI Part 2a for azenosertib in Cyclin E1+ platinum-resistant ovarian cancer.
Topline data from DENALI Part 2 expected by year-end 2026; potential for accelerated approval.
R&D expenses $27.2M vs $49.6M YoY; total operating expenses $45.6M including $7.8M restructuring.
Prior Part 1b data: ORR 34.9%, median DOR 6.3 months in evaluable Cyclin E1+ PROC patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.